A panel of vaccine experts at the Centers for Disease Control and Prevention voted unanimously to recommend the two mRNA vaccines over the Johnson & Johnson vaccine due to concerns about a rare but severe blood clotting condition.

“I just have a real problem with a recommendation for anyone to get a vaccine that 1 per 100,000 women ages 30 to 49 years old will have a condition with a case fatality rate of 15%,” said Pablo Sanchez, a member of the CDC’s Advisory Committee on Immunization Practices and a professor of pediatrics at Ohio State University.

Recommended Stories

FDA authorizes Pfizer-BioNTech COVID-19 boosters for children 5-11

Authorities leaning toward resuming Johnson & Johnson vaccine with warning

Over 1 million people have obtained COVID-19 booster shots without FDA approval